Latest Conference Articles

Study results show that intrathecal ziconotide provides significant pain relief for patients with refractory painful myelopathies and neuropathies.

Better understanding of the processes of cortical rewiring and recruitment will enable researchers to develop more effective treatments for multiple sclerosis.

Results from the multicenter SET study suggest that smoking, response to Epstein Barr virus, and other environmental factors contribute to disease progression in multiple sclerosis.

MRI studies show comorbid depression and fatigue may have an effect on gray matter atrophy in specific regions of the brain in patients with multiple sclerosis.

MRI data shows that multiple sclerosis patients with central neuropathic pain often have lesions focused in the center of the mid-thoracic spinal cord.

Electronic data can be used to create "virtual cohorts" to rapidly implement studies of MS disease activity, comorbidities, pharmacogenomics, and presymptomatic disease.

More than 90% of participants in the Therapy Optimization in Multiple Sclerosis (TOP MS) study were still on their original disease modifying therapy at one year follow-up.

Study results show that IPX066 demonstrated a favorable tolerability profile throughout extended dosing in early Parkinson's disease (PD) and during the long-term management of patients with advanced PD.

Updated guideline recommends athletes with suspected concussion "be immediately taken out of the game and not returned until assessed by a licensed health care professional trained in concussion, return to play slowly and only after all acute symptoms are gone."

In the MOTION and SETTLE studies, safinamide was shown to be effective in the treatment of patients with Parkinson's disease as add-on therapy to a stable dose of a single dopamine agonist and as add-on therapy for patients taking levodopa.

Switching from oral administration of the non-ergoline dopamine agonist, rotigotine, to a transdermal delivery system may improve gastrointestinal symptoms for patients with Parkinson's disease.

Fernando Figueira, MD, and his associates from the Hospital São Francisco, in Rio De Janeiro, Brazil, called for expanded requirements for "disease-free" designation in multiple sclerosis (MS) patients in a Multiple Sclerosis Treatment poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting.

In the Multiple Sclerosis Treatment Safety poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting, Barry Singer, a neurologist at the Missouri Baptist Medical Center, in St. Louis, and founder and director of the MS Center for Innovations in Care, and his co-authors presented an analysis of infection rates in three placebo-controlled teriflunomide studies.

In the Multiple Sclerosis Treatment Safety poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting, Paul O'Connor, of St. Michael's Hospital, in Toronto, and his colleagues presented a study designed to determine whether immune responses to seasonal influenza vaccination are preserved in teriflunomide-treated patients with relapsing forms of multiple sclerosis (RMS).

Seminar at the American Academy of Neurology annual meeting discusses the systematic approach to diagnosing patients with MS, initial medication selection, and changing treatments.

Disease activity, patient preference, and other factors should be considered when selecting DMT for the treatment of multiple sclerosis.

Study results suggest that age and timing of treatment initiation with interferon beta therapy may play a larger role than relapse in long-term disability in patients with multiple sclerosis.

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the SHIFT study's value for cardiologists over various recent heart failure trials.

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the factors cardiologists consider in selecting specific beta blockers for heart failure patients.

Data from the PARTNER cohort A trial show transcatheter aortic valve replacement produces similar mortality rates at one year compared with the standard procedure.

Results from the CORONARY trial show no significant difference at one year between patients with CAD who underwent on-pump vs. off-pump CABG.

Results from the ASTRONAUT trial show that adding aliskiren to standard therapy for chronic heart failure does not improve mortality or rehospitalization rates.

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses treating patients with heart failure with beta-blockers and whether there are any patients in this group who are not good candidates for this treatment.

Study results presented at ACC.13 show that patients with unprotected left main coronary artery disease treated with double kissing crush stenting experienced fewer cases of restenosis and other major adverse events compared to patients who received culotte stenting.

Investigators in the expanded HORUS trial using CT scans of ancient mummies from multiple populations and geographic regions report finding evidence of probable or definite atherosclerosis in nearly one-third of samples.

Results from the PARTNER II trial show improvements in 30-day mortality and stroke rates in patients with aortic stenosis who are not surgical candidates who were treated using a newer version of the Sapien transcatheter aortic valve replacement system.

Landmark study results presented at ACC.13 reveal patients with vascular disease treated with niacin therapy face increased risk of myopathy and other adverse events.

Results of the ARMYDA-9 CAROTID trial indicate that loading with 600 mg clopidogrel and high-dose atorvastatin in carotid stent patients independently result in improved neurological outcomes.

Study results presented at ACC.13, the 62nd Annual Scientific Session & Expo of the American College of Cardiology, reveal that in selected STEMI patients, deferred stenting may reduce no-reflow and thrombotic events compared with immediate stenting.

News and updates about AAN 2013, the 65th Annual Meeting of the American Academy of Neurology.